Search 

Mawdsleys are a UK based pharmaceutical wholesaler and leading partner to the healthcare sector and pharmaceutical industry. They offer a range of services:

Pharmaceutical Industry:-
Pharma Third Party Logistics (3PL)
Named Patient Medicine Distribution
Clinical Trial Logistics (inc. blinding, randomisation, labelling, global distribution)
Clinical Trial Materials sourcing & manufacture (inc. IMPs, placebos, over encapsulation)
Regulatory Affairs Services (inc. QP Release / batch certification, QP Services, RP Services)
Patient Information Testing

Healthcare Sector:-
Wholesale Services to hospitals
International Sales
Unlicensed / Named Patient Medicine Supply
Clinical Trial Supply to hospitals and academia (inc. placebos)
Pharmaceutical Overlabelling
Pharmacy IT systems

MedCity is the life sciences cluster organisation for London and the greater south east of England, set up in 2014 by the Mayor of London and the region’s three Academic Health Science Centres. We are funded by the Greater London Authority and Research England, and as a not-for-profit are able to act as a neutral and independent convener across industry, academia and the public sector.

London and the greater south east is home to a rich life sciences cluster, with more than 3,400 life sciences companies, four of the world’s top ten universities, 19 of the top 20 global pharmaceutical companies and world class research centres including The Francis Crick Institute, Harwell Oxford and The Sanger Institute.

Our ambition is for our region to be the unequivocal place of choice for world-leading health and life sciences innovation, R&D, manufacture and commercialisation.

Mereo BioPharma is a UK-based international biopharmaceutical company focused on the development and commercialization of innovative therapeutics that aim to improve outcomes for people in both oncology and rare diseases. Mereo's lead oncology product candidate, etigilimab (Anti-TIGIT) has completed a Phase 1a dose-escalation clinical trial in patients with advanced solid tumors and has been evaluated in a Phase 1b study in combination with nivolumab in select tumor types. Mereo's rare disease product portfolio consists of setrusumab, which has completed a Phase 2b dose-ranging study in adults with osteogenesis imperfecta (OI), as well as alvelestat, which is being investigated in a Phase 2 proof-of-concept clinical trial in patients with alpha-1 antitrypsin deficiency (AATD) and in a Phase 1b/2 clinical trial in COVID-19 respiratory disease.

Midatech Pharma is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. Driven by a team of scientists, engineers, and pharmaceutical development specialists, and led by an experienced management team, Midatech is progressing a pipeline of differentiated therapeutics in areas of high unmet need for the benefit of patients.